RxNT V 6.1.4 wins CCHIT Certified 2011 Standalone ePrescribing certification

NewsGuard 100/100 Score

Networking Technology, Inc. (NTI), the leader in eprescribing, today announced that their nationally recognized eprescribing product, RxNT V 6.1.4, has achieved CCHIT Certified® 2011 Standalone ePrescribing certification. This achievement makes the RxNT eprescribing application the first standalone product in the U.S. to reach the CCHIT Certified 2011 Standalone ePrescribing certification.

“We are assuring our clients that we are committed to helping them receive the maximum Federal stimulus incentives”

“We are assuring our clients that we are committed to helping them receive the maximum Federal stimulus incentives,” states Randy Boldyga, President/CEO of RxNT. “We believe that having the first fully certified standalone ePrescribing product helps validate that we are the premier product in electronic prescribing technology. We are committed to continuing to improve the ePrescribing experience for all U.S. physicians and believe there is still room for improvement. We fully expect that we will be the company that advances technology in this industry over the next decade.”

http://www.rxnt.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy